Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alexion Pharmaceuticals Inc. ALXN

Healthcare Biotechnology
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS... see more

Recent & Breaking News (NDAQ:ALXN)

Five Star Equities Issues New Research Reports on ALXN, AVY, EMN and MPWR

Accesswire October 30, 2013

Alexion Reports Third Quarter 2013 Results

Business Wire October 24, 2013

FDA Grants Breakthrough Therapy Designation to cPMP Replacement Therapy for Patients with Molybdenum Cofactor Deficiency (MoCD) Type A

Business Wire October 24, 2013

Researchers to Present New Data on Soliris® (eculizumab) as a Treatment for Patients with aHUS at ASN Annual Meeting

Business Wire October 16, 2013

Alexion Pharmaceuticals to Report Third Quarter 2013 Results on Thursday, October 24, 2013

Business Wire October 10, 2013

New Data Evaluating Asfotase Alfa in Infants and Young Children with Hypophosphatasia (HPP) Presented at Paediatric Endocrinology Meeting

Business Wire September 22, 2013

NHS England Commissions Soliris® for the Treatment of Atypical Haemolytic Uraemic Syndrome (aHUS)

PR Newswire September 12, 2013

Study Evaluating Eculizumab (Soliris®) in Preventing Antibody-Mediated Rejection (AMR) in Kidney Transplant Recipients Presented at the European Society for Organ Transplantation (ESOT) Annual Congress

Business Wire September 10, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on ALXN, AMGN, CBST and CLDX

Accesswire September 6, 2013

Alexion to Present at Morgan Stanley Global Healthcare Conference

Business Wire September 4, 2013

TSLA, SIRI, ALXN and FB added to NASDAQ Active Stock Watch List at EPR

Accesswire July 25, 2013

Ensemble Therapeutics and Alexion Initiate Collaboration to Discover Macrocycle Drug Candidates Targeting Patients with Severe and Ultra-Rare Disorders

Business Wire July 18, 2013

MNKD, MU, ALXN and GMCR added to NASDAQ Active Stock Watch List at EPR

Accesswire July 16, 2013

Alexion's Soliris® (eculizumab) Receives Positive Opinion from the Committee for Orphan Medicinal Products for Treatment of Neuromyelitis Optica (NMO)

Business Wire July 16, 2013

Alexion Pharmaceuticals to Report Second Quarter 2013 Results on Thursday, July 25, 2013

Business Wire July 11, 2013

Positive Results, Exclusive Agreements, and Orphan Drug Designations - Research Report on Bristol-Myers Squibb, Illumina, Alexion, Health Net, and Emeritus

PR Newswire July 8, 2013

ONXX, ARIA, BMRN and ALXN added to NASDAQ Healthcare Stock Watch List at EPR

Accesswire July 1, 2013

Business Expansions, New Contracts, Product Launches, and Regulatory Approvals - Research Report on Alexion, Actavis, CombiMatrix, Globus Medical, and Teleflex

PR Newswire June 28, 2013

Alexion's Soliris® (eculizumab) Receives Orphan Drug Designation for the Treatment of Neuromyelitis Optica (NMO)

Business Wire June 27, 2013

The Zacks Analyst Blog Highlights:Myriad Genetics, Anika Therapeutics, Biogen Idec, Alexion Pharmaceuticals and Cabot Oil & Gas

PR Newswire June 18, 2013